CClinicalTrials.gg
CompletedNCT00874471Updated Apr 9, 2014

Uveitis Gene-Expression Profiling

An observational study in Uveitis, sponsored by Oregon Health and Science University. Completed at 1 site in United States. Open to participants aged 21 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-04-09.

Sponsored by Oregon Health and Science University · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
280
Ages
21 Years and older
Sex
All
01

Study summary

Uveitis is a group of troublesome diseases that collectively represent a cause of blindness comparable to diabetes. Most forms of uveitis are either infectious or immune-mediated. The investigators propose to create a data base on peripheral blood gene expression for patients with 3 of the most important diseases associated with uveitis: ankylosing spondylitis, sarcoidosis, and Behcet's disease. The investigators will quantitatively measure the expression of consistent alteration in peripheral blood from patients with more than 40,000 gene sequences using microarray gene chip technology. This approach is known to detect systemic immune-mediated disease. The investigators will use this data base to:

  1. Determine if patients with uveitis and ankylosing spondylitis, sarcoidosis, or Behcet's can be distinguished from a normal population or controls with the same systemic disease but no history of uveitis
  2. Determine if the profile of gene expression can distinguish infectious or idiopathic forms of uveitis from patients with spondylitis, sarcoidosis, or Behcet's
  3. Determine how this gene profile changes over time as episodic disease such as spondylitis or Behcet's activates or remits
  4. Correlate the changes in gene expression with the prognosis of the ocular inflammatory process.

The creation of a gene expression data base for patients with uveitis has the potential to clarify the pathogenesis of disease, establish new diagnostic tools, and provide a means for predicting prognosis.

02

Conditions studied

  • Uveitis

Browse trials for

03

In context

Uveitis

335 studies on the registry are indexed under Uveitis; 37 are open to participants now.

This study's enrollment of 280 is above the median of 100 across 107 observational studies indexed under Uveitis.

Browse Uveitis studies →

Lead sponsor

Oregon Health and Science University is the lead sponsor of 676 studies on the registry; 136 are open to participants now.

Of its 49 completed or terminated interventional studies of FDA-regulated products, 36 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Individuals suffering from selected subtypes of uveitis, individuals suffering from selected autoimmune disease and healthy individuals.

Inclusion criteria

  • The study group will include patients aged 21 years or older attending the Uveitis Clinic at the Casey Eye Institute at OHSU who have uveitis of the following subtypes:

    1. ankylosing spondylitis
    2. sarcoidosis
    3. Behçet's disease
    4. toxoplasmosis
    5. herpetic acute retinal necrosis; AND
    6. idiopathic uveitis
  • Another group of patients, also aged 21 years or more, with the following diseases but no uveitis, will be recruited from the Rheumatology Clinic at OHSU as follows:

    1. ankylosing spondylitis
    2. sarcoidosis; AND
    3. Behçet's disease
  • The study group will also include 30 normal control volunteers aged 21 years or older.

Exclusion criteria

Exclusion Criteria:

  • Special/vulnerable subject populations (e.g., mentally impaired persons and children) will not be enrolled.
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
280 participants (actual)

Groups and cohorts

  • sarcoidosis
  • ankylosing spondylitis
  • Behcet's disease
  • toxoplasmosis
  • herpetic acute retinal necrosis
  • idiopathic uveitis
  • ankylosing spondylitis (no uveitis)
  • sarcoidosis (no uveitis)
  • Behcet's disease (no uveitis)
  • normal control
06

What researchers measure

Primary outcomes

  1. Correlation of blood transcriptome with form of uveitis

    Time frame: time of office visit for disease evaluation

07

Study locations

1 site
  • Oregon Health & Science University
    Portland, Oregon 97239-3098, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 9, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00874471
Lead sponsor
Oregon Health and Science University
Responsible party
Jim Rosenbaum (Professor, Oregon Health and Science University) — Principal investigator
First posted
Apr 2, 2009
Start date
Jun 2005
Primary completion
Jul 2010
Last update
Apr 9, 2014

Study contacts

James Rosenbaum, MD
principal investigator · Oregon Health and Science University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion